Table 2.
Univariate analysis of risk factors for mortality from all causes or respiratory failure by day 100 after RSV LRD
| Overall mortality | Mortality from respiratory failure | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P Value | HR | 95% CI | P Value | |
| Transplant year | ||||||
| 1989-1996 | 1.00 | 1.00 | ||||
| 1997-2001 | 0.59 | 0.3-1.3 | 0.180 | 0.75 | 0.3-1.9 | 0.548 |
| 2002-2010 | 0.54 | 0.2-1.3 | 0.155 | 0.59 | 0.2-1.7 | 0.327 |
| Stem cell source | ||||||
| Peripheral blood stem cell | 1.00 | 1.00 | ||||
| Bone marrow | 3.94 | 1.8-8.7 | <.001 | 4.31 | 1.6-12 | 0.004 |
| Cord blood | 1.07 | 0.1-8.6 | 0.947 | 1.71 | 0.2-15 | 0.626 |
| Donor type | ||||||
| Autologous | 1.00 | 1.00 | ||||
| Allogeneic | 1.91 | 0.7-5.4 | 0.222 | 5.60 | 0.8-42 | 0.092 |
| Conditioning regimen | ||||||
| MA + TBI (> 12Gy) | 1.00 | 1.00 | ||||
| MA ± low TBI | 0.78 | 0.4-1.7 | 0.524 | 0.34 | 0.1-1.1 | 0.081 |
| Reduced intensity conditioning | 0.50 | 0.2-1.4 | 0.199 | 0.64 | 0.2-1.9 | 0.424 |
| White blood cell counts | ||||||
| > 1000 ×106/L | 1.00 | 1.00 | ||||
| ≤ 1000 ×106/L | 2.29 | 1.2-4.4 | 0.015 | 2.16 | 1.0-4.8 | 0.060 |
| Co-pathogen | ||||||
| None | 1.00 | 1.00 | ||||
| Any pathogen | 1.36 | 0.7-2.8 | 0.406 | 0.80 | 0.3-2.2 | 0.671 |
| Multiple pathogens | 1.83 | 0.5-6.1 | 0.331 | 2.35 | 0.7-8.1 | 0.177 |
| Oxygen at diagnosis | ||||||
| None | 1.00 | 1.00 | ||||
| ≤ 2L/minute | 0.71 | 0.2-3.3 | 0.656 | 1.58 | 0.3-8.7 | 0.596 |
| > 2L/minute | 3.13 | 1.4-7.1 | 0.006 | 5.15 | 1.7-16 | 0.005 |
| Mechanical ventilation | 6.21 | 2.2-18 | <.001 | 11.2 | 3.0-42 | <.001 |
| Ribavirin use pre diagnosis | ||||||
| None | 1.00 | 1.00 | ||||
| < 5 days | 0.67 | 0.2-1.9 | 0.450 | 0.23 | 0.0-1.7 | 0.148 |
| ≥ 5 days | 0.43 | 0.2-1.2 | 0.120 | 0.44 | 0.1-1.5 | 0.191 |
| Ab-based treatment as time dependent | ||||||
| None/Low-dose | 1.00 | 1.00 | ||||
| High-dose | 1.17 | 0.5-2.8 | 0.727 | 1.41 | 0.5-3.9 | 0.510 |
| Palivizumab* | 0.74 | 0.3-1.6 | 0.450 | 0.76 | 0.3-2.0 | 0.567 |
All variables in Table 1 were used for the univariate analysis. Only variables with p < 0.2 in any analysis, except for Ab-based treatment are shown in this table. The following parameters were not significantly associated; gender, age at RSV LRD, days between transplant and RSV LRD, diagnosis, disease risk at transplantation, %FEV1/FVC pre RSV LRD, %TLC pre RSV LRD, lymphocyte count, steroid use at diagnosis, GVHD prophylaxis, recipient CMV serostatus, and GVHD in lung at RSV LRD.
This includes two patients who received both palivizumab and high-does intravenous immunoglobulin.
Abbreviations; MA: myeloablative conditioning, TBI: total body irradiation, Ab: antibody, FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity %TLC: percentage of predicted total lung capacity, GVHD: graft versus host disease, CMV: cytomegalovirus